Abbott Laboratories 10-Q quarterly reports

Abbott Laboratories reported strong Q2 2026 results, with net sales increasing 13.0% to $12.59 billion, largely driven by the recent acquisition of Exact Sciences.

Abbott Laboratories reported a 6.9% increase in net sales for the third quarter of 2025, driven by robust performance in its Medical Devices segment, despite a decline in COVID-19 testing sales.

Abbott Laboratories reported robust second-quarter 2025 financial results, with net sales increasing 7.4% and diluted EPS rising 36.5%, primarily fueled by strong performance in its Medical Devices segment.

Abbott Laboratories announces increased net sales and earnings for the first quarter of 2025, driven by growth in Medical Devices, Established Pharmaceutical Products, and Nutritional Products.

Abbott Laboratories' third-quarter results show a 7.4% increase in sales excluding foreign exchange impacts, driven by growth in medical devices and established pharmaceuticals, despite a decline in COVID-19 testing revenue.

Abbott Laboratories' second quarter results show a 4% increase in sales, driven by strong performance in Medical Devices and Nutritional Products, despite a decline in COVID-19 testing revenue.

Abbott Laboratories' first quarter 2024 results show a 2.2% increase in net sales, driven by strong performance in the Medical Devices segment, despite a decline in COVID-19 testing related sales.